STING1 and neoplasm: To assess how the Janus nanoparticles can change the intratumoral immune landscape, we performed single-cell RNA sequencing (scRNA-seq) on tumor-infiltrating CD8+ T cells from 4T1 breast tumors upon STING agonist delivery with or without α-PD1 antibody treatment.